Irinotecan in the treatment of small cell lung cancer: a review of patient safety considerations-Reference-Cited by-同舟云学术

Irinotecan in the treatment of small cell lung cancer: a review of patient safety considerations

Published:2006-02-27 Issue:2 Volume:5 Page:303-312
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Kawahara Masaaki¹

Affiliation:

1. Director, Department of Medical Services, National Hospital Organization Kinki-chuo Chest Medical Center, 1180 Nagasone, Sakai, Osaka, 591-8555, Japan.

Publisher

Informa Healthcare

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1517/14740338.5.2.303

Reference60 articles.

1. Estimates of the worldwide mortality from 25 cancers in 1990

2. Small cell lung cancer: state of the art and future perspectives

3. First-line chemotherapy in metastatic small-cell lung cancer (SCLC)

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Construction and application of a high-content analysis for identifying human carboxylesterase 2 inhibitors in living cell system;Analytical and Bioanalytical Chemistry;2020-03-02

2. Modulations in the Peripheral Immune System of Glioblastoma Patient Is Connected to Therapy and Tumor Progression—A Case Report from the IMMO-GLIO-01 Trial;Frontiers in Neurology;2017-06-23

3. The Inhibitory Effect of Ciprofloxacin on the β-Glucuronidase-mediated Deconjugation of the Irinotecan Metabolite SN-38-G;Basic & Clinical Pharmacology & Toxicology;2015-12-02

4. Chemistry and Biology of Camptothecin and its Derivatives;Natural Products;2013

5. Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation;Journal of Pharmacy and Pharmacology;2011-04-07